San Francisco, California based Amarantus Bioscience Holdings, Inc. just announced that Dr. David Lowe has joined their Board of Directors. Dr. Lowe is currently the President & CEO of a Switzerland-based neuroscience consulting firm called NeuroAssets and brings over 35 years of expertise in the identification of investment opportunities in central nervous system (CNS) disorders and the development of therapeutics for CNS diseases. Amarantus’ lead drug candidate is MANF, a highly potent growth factor that has shown anti-apoptotic activity. Amarantus is currently investing in the development of MANF for the treatment of Parkinson’s Disease and Ischemic Heart Disease. However, now that Dr. Lowe is “on-board” we may see a “reprioritizing [of] the MANF pipeline.” Dr. Lowe is especially interested in testing MANF in orphan indications. Multiple groups have shown the importance and potential therapeutic potential of growth factors and anti-apoptotic therapeutics in ALS, let’s hope that Dr. Lowe has ALS on his short list for orphan indications.
Click here to read the full story.Share this: